Somatropin Interactions: Alcohol, Caffeine, Food and Other Compounds

This page is for educational purposes only and is not medical advice; consult a licensed physician about any question involving a prescription medicine, including somatropin. Nothing here describes how a compound should be used, combined or scheduled — it summarises what published studies examined and what researchers reported.

What the published record actually contains

Somatropin is recombinant human growth hormone. In the literature surveyed for this page, it appears mostly in three kinds of papers: indication-specific clinical reviews, formulation and delivery research, and post-approval safety datasets. A 2004 review described somatropin (Zorbtive) in short bowel syndrome, where it was given to patients already receiving specialised nutritional support (PMID 15200350), and a pharmacokinetic study examined how PEGylation of recombinant human growth hormone affected its clearance in humans (PMID 18802875). Neither of those papers, nor any other in this verified set, was designed as a drug–drug or drug–beverage interaction trial.

That distinction matters. An interaction finding requires a study that deliberately co-administered two agents and measured a change in exposure, response or adverse events. A review that mentions two therapies being used in the same patient population is describing clinical context, not an interaction result. The sections below keep those categories separate.

Somatropin and Alcohol: What Studies Report

No study in this verified evidence set examined alcohol together with somatropin. There is no trial here that measured somatropin pharmacokinetics after alcohol intake, no pharmacovigilance analysis in this set that isolated alcohol as a co-exposure, and no clinical report linking the two. Any statement that alcohol "blocks", "reduces" or "amplifies" somatropin would not be traceable to the papers listed at the end of this page.

The mechanistic reasoning researchers use (reasoning, not evidence)

Where no interaction study exists, investigators typically reason from what is known about the molecule. Somatropin is a protein, and structural characterisation work has described somatropin and its variants along with the analytical methods used to distinguish them (PMID 15659284). It is administered parenterally, with a review of growth hormone delivery devices describing injection systems developed in part to support treatment adherence (PMID 27718757). From those two facts, researchers reason that somatropin does not undergo the gastrointestinal absorption and hepatic first-pass steps through which many oral drugs interact with alcohol. That is an inference about plausibility — it is explicitly not a finding, and it says nothing about downstream endocrine or metabolic overlap, which the verified papers did not test.

Somatropin and Caffeine: What Studies Report

No study in this verified set examined caffeine with somatropin. No pharmacokinetic crossover, no stimulant co-administration arm, and no safety analysis separating caffeine users appears in these papers. The same reasoning framework applies as for alcohol: somatropin's protein structure and the analytical methods used to characterise it have been described (PMID 15659284), and the clearance work that does exist concerned chemical modification of the molecule itself rather than co-administered substances, since the study assessed how PEGylation changed somatropin clearance in humans (PMID 18802875). Readers encountering confident claims about caffeine and growth hormone should note that such claims are not supported by the literature catalogued here.

Food, Fasting and Nutritional Support

This is the one area where the verified literature does describe somatropin being used alongside nutrition deliberately, although still not as a formal food-effect study. The 2004 review of somatropin in short bowel syndrome described its place in patients receiving specialised nutritional support (PMID 15200350). A broader 2014 review of pharmacologic options for intestinal rehabilitation in short bowel syndrome discussed growth hormone among the agents used to support intestinal adaptation in patients dependent on parenteral nutrition (PMID 24615689).

In those settings, nutrition was not a confounder to be controlled out — it was part of the therapeutic context the reviews described. What the papers did not do was compare somatropin exposure in fed versus fasted states, or test whether meal timing changed response. Claims about "fasted administration" improving somatropin outcomes are not findings from these reviews; researchers who raise the question generally reason from the injected route described in the delivery-device literature (PMID 27718757), which again is reasoning rather than measurement.

Other Compounds Commonly Asked About

Several verified papers describe somatropin or growth hormone appearing in treatment landscapes alongside other drugs. These are co-use contexts reported in reviews, not interaction measurements.

• Agents used in intestinal rehabilitation. The 2014 review surveyed the pharmacologic options available for intestinal rehabilitation in short bowel syndrome, with growth hormone among the therapies discussed (PMID 24615689).
• Endocrine therapy in paediatric growth settings. A 2004 review set out current treatment options for central precocious puberty, a field in which growth-related endpoints and hormonal agents are managed together (PMID 15339200), and a separate review examined growth hormone use in children with idiopathic short stature (PMID 15266039).
• Neuromuscular disease trials. A Cochrane review assessed drug treatments studied in randomised trials for spinal muscular atrophy types II and III (PMID 32006461), illustrating how growth hormone has been evaluated against defined endpoints rather than as an add-on to other compounds.

None of those reviews reported a measured pharmacokinetic interaction with somatropin. Where researchers describe combinations in these fields, the rationale is usually complementary mechanism or shared clinical endpoint, which the reviews state as treatment strategy rather than as interaction data (PMID 24615689).

What Does Change Somatropin Exposure in Published Work

The clearest exposure-altering factors in this literature are structural and route-related, not dietary. The PEGylation study examined the impact of PEG attachment on somatropin clearance in humans (PMID 18802875). Preclinical formulation work developed PLGA- and PEG-based porous microparticles as vehicles for pulmonary somatropin delivery, testing an alternative to injection (PMID 37661024). A review of growth hormone delivery devices described the features of current systems and their potential role in treatment adherence (PMID 27718757).

Researchers also distinguish between somatropin products. Analytical work has characterised somatropin and its variants and the methods used to assess them (PMID 15659284), and biosimilar literature has examined whether follow-on biologics behave comparably to reference products, including a report on biosimilar granulocyte-colony-stimulating factor used for healthy donor stem cell mobilisation as a case study in biosimilar confidence (PMID 24965197).

Interaction topics and the evidence behind them

Adverse Events and Co-Exposure: What Studies Report

Safety information about somatropin in this set comes from indication reviews and post-approval surveillance rather than from combination studies. A 2023 analysis reported long-term real-world post-approval safety data covering multiple biosimilars from a single marketing-authorisation holder more than 18 years after that holder's first biosimilar launch (PMID 37902937). A review of growth hormone use in children with idiopathic short stature addressed the efficacy and safety considerations debated in that population (PMID 15266039), and the short bowel syndrome review discussed somatropin's tolerability profile within that indication (PMID 15200350).

Spontaneous-reporting databases are the usual tool for detecting adverse signals that involve several medicines at once. A 2025 real-world pharmacovigilance analysis of medication-associated memory disorder demonstrated that approach, using disproportionality methods on large post-marketing report collections (PMID 40816367). Such analyses can flag associations for further study, but they cannot establish causation and do not substitute for a controlled interaction trial.

How an Interaction Would Have to Be Demonstrated

1. Controlled pharmacokinetics. Exposure measured with and without the second substance, as in the human clearance work on PEGylated somatropin (PMID 18802875).
2. Randomised clinical endpoints. Trials with pre-specified outcomes, the design standard applied in the Cochrane assessment of drug treatment for spinal muscular atrophy types II and III (PMID 32006461).
3. Surveillance signal detection. Large-scale post-marketing report analysis, as illustrated by the 2025 memory-disorder pharmacovigilance study (PMID 40816367) and by long-term biosimilar safety reporting (PMID 37902937).

For alcohol and caffeine specifically, none of those three steps has been completed in the literature verified for this page. The honest summary is an absence of data, not a reassurance and not a warning.

Limitations of This Summary

This page reflects a defined set of indexed papers; it is not an exhaustive systematic search, and prescribing information held by regulators and manufacturers may describe interaction language derived from sources outside this set. Several cited reviews date from 2004 and describe treatment landscapes that have since evolved, including the short bowel syndrome review (PMID 15200350) and the idiopathic short stature review (PMID 15266039). Formulation research such as the pulmonary microparticle work remained preclinical in the report described (PMID 37661024). A broader overview of somatropin's pharmacology and studied indications is covered separately in the PeptideU somatropin learn page.

References

• Somatropin (Zorbtive): in short bowel syndrome (Drugs, 2004)
• Pharmacologic options for intestinal rehabilitation in patients with short bowel syndrome (JPEN J Parenter Enteral Nutr, 2014)
• Central precocious puberty: current treatment options (Paediatric Drugs, 2004)
• Growth hormone use in children with idiopathic short stature (The Annals of Pharmacotherapy, 2004)
• PEGylation of somatropin (recombinant human growth hormone): impact on its clearance in humans (Xenobiotica, 2008)
• PLGA and PEG based porous microparticles as vehicles for pulmonary somatropin delivery (European Journal of Pharmaceutics and Biopharmaceutics, 2023)
• Growth hormone delivery devices: current features and potential for enhanced treatment adherence (Expert Opinion on Drug Delivery, 2017)
• Somatropin and its variants: structural characterization and methods of analysis (Pharmeuropa Bio, 2004)
• Long-Term Real-World Post-approval Safety Data of Multiple Biosimilars from One Marketing-Authorization Holder After More than 18 Years Since Their First Biosimilar Launch (Drug Safety, 2023)
• Biosimilar granulocyte-colony-stimulating factor for healthy donor stem cell mobilization: need we be afraid? (Transfusion, 2015)
• Updated insights on memory disorder associated risk of medication: A real-world pharmacovigilance analysis (Journal of Affective Disorders, 2025)
• Drug treatment for spinal muscular atrophy types II and III (Cochrane Database of Systematic Reviews, 2020)